Navigation Links
Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
Date:7/7/2009

PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- Covance Inc. today announced that Steven M. Michael, Ph.D. has joined the company as vice president and chief scientific officer of global bioanalytical services. With 15 years of pharmaceutical industry experience, including bioanalytical research, translational research, and talent development, Dr. Michael will lead scientific, marketing, and business development strategy for Covance's bioanalytical services.

Dr. Michael joins Covance from Pfizer Global Research and Development where he served as executive director of bioanalytical research in Worldwide Pharmacokinetics, Dynamics & Metabolism. As a member of the executive leadership team, he provided strategic leadership for the Worldwide Pharmacokinetics, Dynamics & Metabolism group and led the regulated bioanalytical support of the Pfizer human health portfolio. Dr. Michael's experience also includes drug discovery, drug development, and research technology with focus on bioanalytical research, translational research, biomarkers, and leadership development.

Dr. Michael received a doctorate in analytical chemistry from the University of Michigan. He is a member of the American Society of Mass Spectrometry and the American Association of Pharmaceutical Scientists and has been published in various scientific publications, including Analytical Chemistry, Journal of Pharmaceutical and Biomedical Analysis, and International Journal of Mass Spectrometry and Ion Process.

Offering global flexible capacity and more than 350 bioanalytical scientists with more than 2,600 years of combined industry experience, Covance's bioanalytical services group develops and validates more than 550 methods every year to support drug development from discovery through Phase IV.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
2. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
3. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
5. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
6. Covance Decides to Pursue Its Original Preclinical Strategy in China
7. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
8. Covance Purchases Equity Stake in Caprion Proteomics
9. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
10. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
11. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... and Liege, Belgium (PRWEB) , ... January 17, ... ... solutions for sample preparation and epigenetics research, recently announced a collaboration with the ... a high-sensitivity DNA amplification method for library preparation, following the company’s successful launch ...
(Date:1/16/2017)... --  Valentin A. Pavlov, PhD , associate investigator, and ... of The Feinstein Institute for Medical Research ... nervous system regulates the immune system, which will help ... devices to treat disease and injury. The analysis is ... The paper examines various studies which further define the ...
(Date:1/14/2017)... , Jan. 13, 2017  The Alliance for Safe ... response to FDA final guidance on biologic ... continued leadership in emphasizing the importance of distinct naming ... aware of the benefits biosimilars will bring to patients, ... Yet the portion of the Guidance dealing with ...
(Date:1/13/2017)... ... 13, 2017 , ... FireflySci has been busy rolling out ... diverse customer base. The latest entry in this field is a series of ... Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, 10x2 and 10x4 ...
Breaking Biology Technology:
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):